Stocks · Health care · Biological Products, (No Diagnostic Substances)

C4 Therapeutics, Inc.

CCCC Clue Score37
United States Fiscal year ends December CIK 0001662579 Results filed 5 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Utpal Koppikar
8 Feb 2023
Director
Buy
5,667
$5.60
$31.74K
Andrew Hirsch
12 Apr 2022
President & CEO
Buy
10,000
$8.40
$84.00K
Malcolm Salter
6 Oct 2020
Director
Buy
1,315
$19.00
$24.99K
Marc A Cohen
6 Oct 2020
Director
Buy
5,030
$19.00
$95.57K
William McKee
6 Oct 2020
Chief Financial Officer
Buy
5,263
$19.00
$100.00K

What was left out

Form 4 filings counted 260
Amendments (4/A) skipped 8
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 12
Sales at will 40
Transactions with no price 0
Shares from compensation/vesting 14,138,520
Sales filed before the plan box existed 39
History held since 5 Oct 2020